The ongoing ALNEO trial is enrolling patients with potentially resectable stage III ALK-positive NSCLC (any T with N2, or T4N0-1) to receive neoadjuvant oral alectinib followed by surgery and adjuvant alectinib for 24 cycles (96 weeks). Here, ALK is linked to non-small cell lung carcinoma.